OCUGEN, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
OCUGEN, INC. (OCGN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $2.00 thousand as of 2017-06-30, per its 10-Q filed 2017-08-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2017-08-10
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $2.00K.
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $6.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2017-06-30 | $2.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $6.00K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |